Corrigendum to “ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe”: Ann Oncol 2016; 27 (8): 1423-1443 (Annals of Oncology (2016) 27(8) (1423–1443), (S092375341934743X), (10.1093/annonc/mdw213));ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1423-1443

  Cherny, Nathan I ^a   Sullivan, R ^b   Torode, J ^c   Saar, M ^d   Eniu, A ^e  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Union for International Cancer Control   (Switzerland)

^d TARTU UNIVERSITY HOSPITAL   (Estonia)

^e Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

Anticancer medications; Cost of medications; ESMO; Medication shortages; Pharmaco economics; Public policy

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DACARBAZINE; ERLOTINIB; EVEROLIMUS; FOTEMUSTINE; FULVESTRANT; GEFITINIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VEMURAFENIB; VINBLASTINE;

ARTICLE; COLORECTAL CANCER; DRUG COST; DRUG MEGADOSE; EASTERN EUROPE; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GERM CELL TUMOR; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DISPARITY; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; METASTATIC BREAST CANCER; OUT OF POCKET COST; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REIMBURSEMENT; SARCOMA; STOMACH CANCER; WESTERN EUROPE; BREAST TUMOR; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL TUMOR; ECONOMICS; EUROPE; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; MALE; NON SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; EUROPE; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MELANOMA; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84984984313     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1016/j.annonc.2020.09.002     Document Type: Erratum

References (80)

1. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 2013; 31: 3600-3604.
2. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009; 27: 2111-2113.
3. Bigdeli M, Jacobs B, Tomson G et al. Access to medicines from a health system perspective. Health Policy Plan 2013; 28: 692-704.
4. Smith SK, Nicolla J, Zafar SY. Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. J Oncol Pract 2014; 10: e368-e372.
5. de Souza JA, Wong YN. Financial distress in cancer patients. J Med Person 2013; 11: 73-77.
6. Zafar SY, Peppercorn JM, Schrag D et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18: 381-390.
7. Vogler S, Zimmermann N, Habl C. Understanding the components of pharmaceutical expenditure-overview of pharmaceutical policies influencing expenditure across European countries. GaBi J 2013; 2: 178-187.
8. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect 2015; 29: 139-162.
9. Cheema PK, Gavura S, Migus M et al. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol 2012; 19: e165-e176.
10. United Nations development program. Human Development Reports. Geneva: United Nations 2014. http://hdr.undp.org/en/data (June 2016, date last accessed).
11. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165-1174.
12. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23-34.
13. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
14. Munro AJ. Comparative cancer survival in European countries. Br Med Bull 2014; 110: 5-22.
15. Gatta G, Trama A, Capocaccia R. Variations in cancer survival and patterns of care across Europe: roles of wealth and health-care organization. J Natl Cancer Inst Monographs 2013; 2013: 79-87.
16. European Commission. Communication from the Commission on Effective, Accessible and Resilient Health Systems. Brussels 2014; 17. http://ec.europa.eu/ health/healthcare/docs/com2014_2215_final_en.pdf (June 2016, date last accessed).
17. Huber M, Stanciole A, Wahlbeck K et al. Quality in and Equality of Access to Healthcare Services. European Commission 2008; 160. http://www.euro.centre. org/data/1237457784_41597.pdf (June 2016, date last accessed).
18. Pauwels K, Huys I, Casteels M, Simoens S. Drug shortages in European countries: a trade-off between market attractiveness and cost containment? BMC Health Serv Res 2014; 14: 438.
19. Pauwels K, Simoens S, Casteels M, Huys I. Insights into European drug shortages: a survey of hospital pharmacists. PLoS One 2015; 10; doi:10.1371/journal. pone.0119322.
20. Cherny NI, Baselga J, de Conno F, Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010; 21: 615-626.
21. Cherny NI, Cleary J, Scholten W et al. The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology. Ann Oncol 2013; 24: xi7-xi13.
22. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
23. World Health Organization. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2015 In WHO Technical Report Series. Geneva: World Health Association 2015; 553. http://apps.who.int/iris/bitstream/10665/ 189763/1/9789241209946_eng.pdf?ua=1 (June 2016, date last accessed).
24. European Association of Hospital Pharmacists. Medicines Shortages on European Hospitals: The Evidence and Case for Action. Brussels: European Association of Hospital Pharmacists 2014; 48. www.eahp.eu/sites/default/files/shortages_ report05online.pdf (June 2016, date last accessed).
25. European Medicines Agency. Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/Good Manufacturing Practice Compliance Problems. London: European Medicines Agency 2012. http://www.ema.europa.eu/ docs/en_GB/document_library/Other/2012/2011/WC500135113.pdf (June 2016, date last accessed).
26. European Medicines Agency. Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/Good Manufacturing Practice Compliance Problems: Implementation Plan 2012-2015. London: European Medicines Agency 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/11/ WC500135113.pdf (June 2016, date last accessed).
27. von der Schulenburg F, Vandoros S, Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Econ Rev 2011; 1: 18.
28. Prinja S, Kanavos P, Kumar R. Health care inequities in north India: role of public sector in universalizing health care. Indian J Med Res 2012; 136: 421-431.
29. European Society for Medical Oncology. ESMO 2020 Vision. Lugano: ESMO 2015; 12. www.esmo.org/content/download/68849/1233986/file/ESMO-1232020- vision-brochure.pdf (June 2016, date last accessed).
30. Karanikolos M, Mladovsky P, Cylus J et al. Financial crisis, austerity, and health in Europe. Lancet 2013; 381: 1323-1331.
31. Sullivan R, Aggarwal A. Health policy: putting a price on cancer. Nat Rev Clin Oncol 2016; 13: 137-138.
32. Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol 2016; 69: 438-447.
33. Pfister DG. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. J Clin Oncol 2013; 31: 3487-3489.
34. Hoen E. A study of medicine pricing issues with recommendations for improving access to cancer medication. OXFAM 2014; 54. https://www.oxfam.org/sites/ www.oxfam.org/files/file_attachments/rr-access-cancer-treatment-inequality-040215- en.pdf (June 2016, date last accessed).
35. Organisation for Economic Co-operation and Development. Pharmaceutical Pricing Policies in a Global Market. In OECD Health Policy Studies 2008; pp219. http:// apps.who.int/medicinedocs/documents/s19834en/s19834en.pdf (June 2016, date last accessed).
36. Kantarjian HM. Charging what the market will bear is inappropriate. Clin Adv Hematol Oncol 2014; 12: 63.
37. Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ 2015; 24: 294-301.
38. Mailankody S, Prasad V. Five years of cancer drug approvals innovation, efficacy, and costs. JAMA Oncol 2015; 1: 539-540.
39. Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res 2013; 13: 735-741.
40. Vogler S, Vitry A, Babar Z-U-D. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol 2016; 17: 39-47.
41. van Harten WH, Wind A, de Paoli P et al. Actual costs of cancer drugs in 15 European countries. Lancet Oncol 2016; 17: 18-20.
42. Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law 2011; 6: 337-367.
43. Savage P, Mahmoud S. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014. Br J Cancer 2015; 112: 1037-1041.
44. IMS Institute for Healthcare Informatics. Developments in Cancer Treatments, Market Dynamics, Patient Access and Value: Global Oncology Trend Report 2015. Parsippany, NJ: IMS Institute for Healthcare Informatics 2015; 47.
45. EvaluatePharma®. EvaluatePharma® World Preview 2014, Outlook to 2020. 2014; 39. http://info.evaluategroup.com/rs/evaluatepharmaltd/images/EP240614. pdf (June 2016, date last accessed).
46. Anderson R. Pharmaceutical Industry Gets High on Fat Profits. BBC Business News 2014. http://www.bbc.com/news/business-28212223 (June 2016, date last accessed).
47. Chen L. The Most Profitable Industries In 2015. Forbes 2015; Sept 23: http://www. forbes.com/sites/liyanchen/2015/2009/2023/the-most-profitable-industries-in-2015/ #2198bd2016e07712 (June 2016, date last accessed).
48. Kantarjian H, Zwelling L. Cancer drug prices and the free-market forces. Cancer 2013; 119: 3903-3905.
49. Kushnick H. Pricing cancer drugs: when does pricing become profiteering? AMA J Ethics 2014; 17: 750-753.
50. Raftery J. Value based pricing: can it work? BMJ 2013; 347: f5941.
51. Danzon PM, Taylor E. Drug pricing and value in oncology. Oncologist 2010; 15 (Suppl. 1): 24-31.
52. Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol 2015; 2: 1-3.
53. McKneally MF, Dickens BM, Meslin EM, Singer PA. Bioethics for clinicians: 13. Resource allocation. CMAJ 1997; 157: 163-167.
54. Emanuel LL. A professional response to demands for accountability: practical recommendations regarding ethical aspects of patient care. Working group on accountability. Ann Intern Med 1996; 124: 240-249.
55. Kahneman D, Knetsch JL, Thaler R. Fairness as a constraint on profit seeking: entitlements in the market. Am Econ Rev 1986; 4: 728-741.
56. Gagnon MA. Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health. J Law Med Ethics 2013; 41: 571-580.
57. Parker-Lue S, Santoro M, Koski G. The ethics and economics of pharmaceutical pricing. Annu Rev Pharmacol Toxicol 2015; 55: 191-206.
58. Balch CM, Saltz L, Wittes RE. In Cancer Care, Cost Matters. New York Times, OCT. 14. 2012; Online http://www.nytimes.com/2012/10/15/opinion/a-hospital-saysno- to-an-11000-a-month-cancer-drug.html (June 2016, date last accessed).
59. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
60. Maraninchi D, Vernant J-P. L'urgence de maîtriser les prix des nouveaux médicaments contre le cancer. Le Figaro 2016. March 14: http://sante.lefigaro.fr/ actualite/2016/2003/2014/24739-lurgence-maitriser-prix-nouveaux-medicamentscontre- cancer (June 2016, date last accessed).
61. Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ 2016; 352: i1284.
62. Gandjour A. Convergence of decision rules for value-based pricing of new innovative drugs. Expert Rev Pharmacoecon Outcomes Res 2015; 15: 209-213.
63. Fojo T, Lo AW. Price, value, and the cost of cancer drugs. Lancet Oncol 2016; 17: 3-5.
64. Faden RR, Chalkidou K. Determining the value of drugs-the evolving British experience. N Engl J Med 2011; 364: 1289-1291.
65. Carlson JJ, Gries KS, Yeung K et al. Current status and trends in performancebased risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy 2014; 12: 231-238.
66. Carlson JJ, Sullivan SD, Garrison LP et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010; 96: 179-190.
67. Greenhalgh J, Bagust A, Boland A et al. Erlotinib and gefitinib for treating nonsmall cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technol Assess 2015; 19: 1-134.
68. de Lima Lopes G, Jr, de Souza JA, Barrios C. Access to cancer medications in low- and middle-income countries. Nat Rev Clin Oncol 2013; 10: 314-322.
69. Glaxo Smith Kline. Health for All. 2014. http://no.gsk.com/media/274688/healthfor- all-factsheet.pdf (June 2016, date last accessed).
70. Ward A. Cancer drugs cut as UK budget clampdown bites. Financial Times 2015. http://www.ft.com/intl/cms/s/0/01ac9236-5327-9211e9235-b9029- b9239d9250a9274fd9214.html#axzz9234AJ9298R9234rW (June 2016, date last accessed).
71. Ottersen OP, Dasgupta J, Blouin C et al. The political origins of health inequity: prospects for change. Lancet 2014; 383: 630-667.
72. Boseley S. Pig Pharma's Worst Nightmare. The Guardian 2016; Jan 26 2016. http:// www.theguardian.com/society/2016/jan/2026/big-pharmas-worst-nightmare (June 2016, date last accessed).
73. Murphy E. Panel: Compulsory Licensing Could Address High-Priced Medicines in Europe. Intellectual Property Watch 2015. http://www.ip-watch.org/2015/2005/ 2028/speakers-compulsory-licensing-could-address-high-priced-medicines-in-europe/ (June 2016, date last accessed).
74. El Said M, Kapczynski A. Access to medicines: the role of intellectual property law and policy. Global Commission on HIV and the Law Working Paper, 2011; 19. http:// hivlawcommission.org/index.php/report-working-papers?task=document.viewdoc&id=86 (June 2016, date last accessed).
75. World Trade Organization. Compulsory Licensing of Pharmaceuticals and TRIPS. https://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm (June 2016, date last accessed).
76. Herget G. WTO approves TRIPS amendment on importing under compulsory licensing. HIVAIDS Policy Law Rev 2006; 11: 23-24.
77. Kapp C. World Trade Organisation reaches agreement on generic medicines. New deal will make it easier for poorer countries to import cut-price generic drugs made under compulsory licensing. Lancet 2003; 362: 807.
78. Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med 2012; 9: e1001154.
79. Wise J. Patent wars: affordable medicines versus intellectual property rights. BMJ 2014; 348: g1533.
80. Chaudhuri S. The larger implications of the Novartis-Glivec judgment. Econ Polit Wkly 2013; 48: 10-12.